Table of Content


Introduction
Tyrosine Protein Kise JAK3 (Janus Kise 3 or Leukocyte Janus Kise or JAK3 or EC 2.7.10.2) - Overview
Tyrosine Protein Kise JAK3 (Janus Kise 3 or Leukocyte Janus Kise or JAK3 or EC 2.7.10.2) - Therapeutics Development
Tyrosine Protein Kise JAK3 (Janus Kise 3 or Leukocyte Janus Kise or JAK3 or EC 2.7.10.2) - Therapeutics Assessment
Tyrosine Protein Kise JAK3 (Janus Kise 3 or Leukocyte Janus Kise or JAK3 or EC 2.7.10.2) - Companies Involved in Therapeutics Development
Tyrosine Protein Kise JAK3 (Janus Kise 3 or Leukocyte Janus Kise or JAK3 or EC 2.7.10.2) - Drug Profiles
Tyrosine Protein Kise JAK3 (Janus Kise 3 or Leukocyte Janus Kise or JAK3 or EC 2.7.10.2) - Dormant Products
Tyrosine Protein Kise JAK3 (Janus Kise 3 or Leukocyte Janus Kise or JAK3 or EC 2.7.10.2) - Discontinued Products
Tyrosine Protein Kise JAK3 (Janus Kise 3 or Leukocyte Janus Kise or JAK3 or EC 2.7.10.2) - Product Development Milestones
Appendix



List of Figures


Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Stage and Molecule Type, 2021


List of Tables


Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Indications, 2021 (Contd..2)
Number of Products under Development by Companies, 2021
Number of Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Products under Development by Companies, 2021 (Contd..3)
Products under Development by Companies, 2021 (Contd..4)
Products under Development by Companies, 2021 (Contd..5)
Products under Development by Companies, 2021 (Contd..6)
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Aclaris Therapeutics Inc, 2021
Pipeline by Alexion Pharmaceuticals Inc, 2021
Pipeline by Arrien Pharmaceuticals LLC, 2021
Pipeline by Astellas Pharma Inc, 2021
Pipeline by Bristol-Myers Squibb Co, 2021
Pipeline by Celon Pharma SA, 2021
Pipeline by Clevexel Pharma SA, 2021
Pipeline by Daewoong Pharmaceutical Co Ltd, 2021
Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, 2021
Pipeline by Impetis Biosciences Ltd, 2021
Pipeline by Japan Tobacco Inc, 2021
Pipeline by Jiangsu Simcere Pharmaceutical Co Ltd, 2021
Pipeline by KBP BioSciences Co Ltd, 2021
Pipeline by Merck & Co Inc, 2021
Pipeline by MYOS RENS Technology Inc, 2021
Pipeline by Novartis AG, 2021
Pipeline by Oncostellae SL, 2021
Pipeline by Pfizer Inc, 2021
Pipeline by Shenzhen Chipscreen Biosciences Co Ltd, 2021
Pipeline by Sienna Biopharmaceuticals Inc, 2021
Pipeline by Theravance Biopharma Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Dormant Products, 2021 (Contd..2)
Dormant Products, 2021 (Contd..3)
Discontinued Products, 2021